EGFR and colorectal cancer: In addition, the first-line chemotherapy for patients with RAS wild-type colorectal cancer includes a combination of the anti-epidermal growth factor receptor (EGFR) antibodies, cetuximab and panitumumab, in addition to conventional chemotherapy [3].